NICORETTE

Manufacturer
Haleon US Holdings LLC
Effective date
2024-03-05
Label type
HUMAN OTC DRUG LABEL
Version
15
Source
full-release
Hydrated at
2026-06-01 00:09:29

Label at a glance#

ProductNICORETTE
Active ingredientNICOTINE
Label structure12 sections

Dosage and administration

if you are under 18 years of age, ask a doctor before use. No studies have been done to show if this product will work for you. before using this product, read the enclosed User’s Guide for complete directions and other important information begin using the lozenge on your quit day if you smoke your first cigarette within 30 minutes of waking up, use 4 mg nicotine lozenge if you smoke your first cigarette more tha...

Label contents#

Full prescribing information#

Active ingredient (in each lozenge) (2 mg)

OTC - ACTIVE INGREDIENT SECTION

Nicotine polacrilex, 2 mg

Active ingredient (in each lozenge) (4 mg)

OTC - ACTIVE INGREDIENT SECTION

Nicotine polacrilex, 4 mg

Purpose

OTC - PURPOSE SECTION

Stop smoking aid

Use

INDICATIONS & USAGE SECTION

  • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

Warnings

WARNINGS SECTION

If you are pregnant or breast-feeding, only use this medicine on the advice of your health care provider.

OTC - PREGNANCY OR BREAST FEEDING SECTION

Smoking can seriously harm your child. Try to stop smoking without using any nicotine replacement medicine. This medicine is believed to be safer than smoking. However, the risks to your child from this medicine are not fully known.

Ask a doctor before use if you have

OTC - ASK DOCTOR SECTION

  • heart disease, recent heart attack, or irregular heartbeat. Nicotine can increase your heart rate.
  • high blood pressure not controlled with medication. Nicotine can increase your blood pressure.
  • stomach ulcer or diabetes
  • history of seizures

Ask a doctor or pharmacist before use if you are

OTC - ASK DOCTOR/PHARMACIST SECTION

  • using a non-nicotine stop smoking drug
  • taking a prescription medicine for depression or asthma. Your prescription dose may need to be adjusted.

Stop use and ask a doctor if

OTC - STOP USE SECTION

  • mouth problems occur
  • persistent indigestion or severe sore throat occurs
  • irregular heartbeat or palpitations occur
  • you get symptoms of nicotine overdose such as nausea, vomiting, dizziness, diarrhea, weakness and rapid heartbeat
  • you have symptoms of an allergic reaction (such as difficulty breathing or rash)

Keep out of reach of children and pets.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Nicotine lozenges may have enough nicotine to make children and pets sick. If you need to remove the lozenge, wrap it in paper and throw away in the trash. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions (2 mg Lozenge)

DOSAGE & ADMINISTRATION SECTION

  • if you are under 18 years of age, ask a doctor before use. No studies have been done to show if this product will work for you.
  • before using this product, read the enclosed User’s Guide for complete directions and other important information
  • begin using the lozenge on your quit day
  • if you smoke your first cigarette within 30 minutes of waking up,use 4 mg nicotine lozenge
  • if you smoke your first cigarette more than 30 minutes after waking up,use 2 mg nicotine lozenge according to the following 12 week schedule:

Weeks 1 to 6

Weeks 7 to 9

Weeks 10 to 12

1 lozenge every 1 to 2 hours

1 lozenge every 2 to 4 hours

1 lozenge every 4 to 8 hours

  • nicotine lozenge is a medicine and must be used a certain way to get the best results
  • place the lozenge in your mouth and allow the lozenge to slowly dissolve. Minimize swallowing. Do not chew or swallow lozenge.
  • you may feel a warm or tingling sensation
  • occasionally move the lozenge from one side of your mouth to the other until completely dissolved
  • do not eat or drink 15 minutes before using or while the lozenge is in your mouth
  • to improve your chances of quitting, use at least 9 lozenges per day for the first 6 weeks
  • do not use more than one lozenge at a time or continuously use one lozenge after another since this may cause you hiccups, heartburn, nausea or other side effects
  • do not use more than 5 lozenges in 6 hours. Do not use more than 20 lozenges per day.
  • it is important to complete treatment. If you feel you need to use the lozenge for a longer period to keep from smoking, talk to your health care provider.

Directions (4 mg Lozenge)

DOSAGE & ADMINISTRATION SECTION

  • if you are under 18 years of age, ask a doctor before use. No studies have been done to show if this product will work for you.
  • before using this product, read the enclosed User’s Guide for complete directions and other important information
  • begin using the lozenge on your quit day
  • if you smoke your first cigarette more than 30 minutes after waking up,use 2 mg nicotine lozenge
  • if you smoke your first cigarette within 30 minutes of waking up,use 4 mg nicotine lozenge according to the following 12 week schedule:

Weeks 1 to 6

Weeks 7 to 9

Weeks 10 to 12

1 lozenge every 1 to 2 hours

1 lozenge every 2 to 4 hours

1 lozenge every 4 to 8 hours

  • nicotine lozenge is a medicine and must be used a certain way to get the best results
  • place the lozenge in your mouth and allow the lozenge to slowly dissolve. Minimize swallowing. Do not chew or swallow lozenge.
  • you may feel a warm or tingling sensation
  • occasionally move the lozenge from one side of your mouth to the other until completely dissolved
  • do not eat or drink 15 minutes before using or while the lozenge is in your mouth
  • to improve your chances of quitting, use at least 9 lozenges per day for the first 6 weeks
  • do not use more than one lozenge at a time or continuously use one lozenge after another since this may cause you hiccups, heartburn, nausea or other side effects
  • do not use more than 5 lozenges in 6 hours. Do not use more than 20 lozenges per day.
  • it is important to complete treatment. If you feel you need to use the lozenge for a longer period to keep from smoking, talk to your health care provider.

Other information

SPL UNCLASSIFIED SECTION

  • store at 20 – 25 oC (68 – 77 oF)
  • keep vial tightly closed and protect from light

Inactive ingredients

INACTIVE INGREDIENT SECTION

acesulfame potassium, calcium polycarbophil, flavors, magnesium stearate, mannitol, potassium bicarbonate, sodium alginate, sodium carbonate, xanthan gum

Questions or comments?

OTC - QUESTIONS SECTION

call toll-free 1-888-569-1743

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0135-0508-02

Nicorette ®

nicotine polacrilex lozenge, 2 mg

stop smoking aid

miniLozenge

Mint

FOR THOSE WHO SMOKE THEIR FIRST CIGARETTE MORE THAN 30 MINUTES AFTER WAKING UP.

If you smoke your first cigarette WITHIN30 MINUTES of waking up, use Nicorette ®  4 mg Lozenge

81 LOZENGES,2 mg Each

(3 Vials of 27)

Opening Directions:

Push in child resistant tab on the vial with thumb.

Flip up the top of vial. Turn upside down and shake to remove lozenge.

TO INCREASE YOUR SUCCESS IN QUITTING:

  1. You must be motivated to quit.
  2. Use Enough– Use at least 9 Nicorette ®mini lozenges per day during the first six weeks.
  3. Use Long Enough– Use Nicorette ®mini lozenges for the full 12 weeks.
  4. Use With a Support Programas directed in the enclosed User’s Guide.
  5. not for sale to those under 18 years of age
  6. proof of age required
  7. not for sale in vending machines or from any source where proof of age cannot be verified

TAMPER EVIDENT FEATURE:Do not use if clear neckband printed "SEALED FOR SAFETY" is missing or broken. Retain outer carton for full product uses, directions and warnings.

For more information and for a FREE individualized stop smoking program, please visit www.Nicorette.comor see inside for more details.

Trademarks are owned by or licensed to the GSK group of companies.

Distributed By:

GSKConsumer Healthcare

Warren, NJ 07059

Made in Switzerland

©2015 GSK group of companies or its licensor. All rights reserved.

104277XB

Nicorette Mini Lozenge 2 mg 81 ct carton
Nicorette Mini Lozenge 2 mg 81 ct carton

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0135-0509-02

Nicorette ®

nicotine polacrilex lozenge, 4mg

stop smoking aid

miniLozenge

Mint

FOR THOSE WHO SMOKE THEIR FIRST CIGARETTE WITHIN 30 MINUTES OF WAKING UP.

If you smoke your first cigarette MORE THAN30 MINUTES after waking up, use Nicorette ®2 mg Lozenge

81 LOZENGES,4 mg Each

(3 Vials of 27)

Opening Directions:

Push in child resistant tab on the vial with thumb.

Flip up the top of vial. Turn upside down and shake to remove lozenge.

TO INCREASE YOUR SUCCESS IN QUITTING:

  1. You must be motivated to quit.
  2. Use Enough– Use at least 9 Nicorette ®mini lozenges per day during the first six weeks.
  3. Use Long Enough– Use Nicorette ®mini lozenges for the full 12 weeks.
  4. Use With a Support Programas directed in the enclosed User’s Guide.
  5. not for sale to those under 18 years of age
  6. proof of age required
  7. not for sale in vending machines or from any source where proof of age cannot be verified

TAMPER EVIDENT FEATURE:Do not use if clear neckband printed "SEALED FOR SAFETY" is missing or broken. Retain outer carton for full product uses, directions and warnings.

For more information and for a FREE individualized stop smoking program, please visit www.Nicorette.comor see inside for more details.

Trademarks are owned by or licensed to the GSK group of companies.

Distributed By:

GSKConsumer Healthcare

Warren, NJ 07059

Made in the Switzerland

©2015 GSK group of companies or its licensor. All rights reserved.

104255XB

Nicorette Mini Lozenge 4 mg 81 ct carton
Nicorette Mini Lozenge 4 mg 81 ct carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
968849Nicorette 2 MG Oral LozengePSN15
968851Nicorette 4 MG Oral LozengePSN15
359817nicotine 2 MG Oral LozengePSN15
359818nicotine 4 MG Oral LozengePSN15
968849nicotine 2 MG Oral Lozenge [Nicorette]SBD15
968851nicotine 4 MG Oral Lozenge [Nicorette]SBD15
359817nicotine 2 MG Oral LozengeSCD15
359818nicotine 4 MG Oral LozengeSCD15
968849Nicorette 2 MG (nicotine polacrilex 11.1 MG) Oral LozengeSY15
968849Nicorette 2 MG Oral LozengeSY15
968849Nicorette 2 MG TrocheSY15
968851Nicorette 4 MG (nicotine polacrilex 22.2 MG) Oral LozengeSY15
968851Nicorette 4 MG Oral LozengeSY15
359817nicotine 2 MG (as nicotine polacrilex 11.1 MG) Oral LozengeSY15
359817nicotine 2 MG TrocheSY15
359818nicotine 4 MG (as nicotine polacrilex 22.2 MG) Oral LozengeSY15
359818nicotine 4 MG TrocheSY15

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NICOTINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
dbebfdf8-6e0c-cfa8-fdbc-e5d7f1bf1562Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
0135-0508-022023-11-02C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-032023-11-02C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-042023-11-02C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-022023-11-02C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-032023-11-02C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-042023-11-02C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-022023-01-30C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-032023-01-30C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-042023-01-30C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-022023-01-30C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-032023-01-30C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-042023-01-30C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-022020-10-20C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-032020-10-20C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-042020-10-20C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-022020-10-20C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-032020-10-20C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-042020-10-20C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-022020-01-31C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-032020-01-31C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0508-042020-01-31C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-022020-01-31C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-032020-01-31C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts
0135-0509-042020-01-31C16284748780-19d75b9d0-7d8c-f424-e053-dadaa90a57ceDrug Facts

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0135-0508-02NICORETTE27 in 1 CONTAINERLOZENGE2715
0135-0508-02NICORETTE3 in 1 CARTONLOZENGE315
0135-0508-03NICORETTE5 in 1 CARTONLOZENGE515
0135-0508-03NICORETTE27 in 1 CONTAINERLOZENGE2715
0135-0508-04NICORETTE20 in 1 CONTAINERLOZENGE2015
0135-0509-02NICORETTE3 in 1 CARTONLOZENGE315
0135-0509-02NICORETTE27 in 1 CONTAINERLOZENGE2715
0135-0509-03NICORETTE5 in 1 CARTONLOZENGE515
0135-0509-03NICORETTE27 in 1 CONTAINERLOZENGE2715
0135-0509-04NICORETTE20 in 1 CONTAINERLOZENGE2015

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0135-0508NICORETTE (NICOTINE POLACRILEX) LOZENGE [HALEON US HOLDINGS LLC]15Current NDC, Legacy NDC, 5 package rows20240307_fdee1637-8049-4bc5-b196-b6d854c9f9f3.zip
0135-0509NICORETTE (NICOTINE POLACRILEX) LOZENGE [HALEON US HOLDINGS LLC]15Legacy NDC, 5 package rows20240307_fdee1637-8049-4bc5-b196-b6d854c9f9f3.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0135-0508-02EA - Each0135-05084cfc8acc-c2c6-4aee-a9b5-21a75902554e12012-07-24
0135-0508-03EA - Each0135-05084f481875-bff3-4635-bf3b-5199434b230512012-07-24
0135-0508-04EA - Each0135-05082108ac5f-c1cc-41bf-8f4d-5e7a53ad071b12017-03-06
0135-0509-02EA - Each0135-0509f97c9b19-e284-4eed-9dac-a897df1f14f412012-07-24
0135-0509-03EA - Each0135-0509aecea704-a2c0-46f9-834e-464df19a333612012-07-24
0135-0509-04EA - Each0135-050906cf46ae-b1f7-4224-9c7c-d9935cb0431812017-03-06

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
NICOTINEACTIVE INGREDIENT6M3C89ZY6R9
NICOTINEACTIVE MOIETY6M3C89ZY6R9
ACESULFAME POTASSIUMINACTIVE INGREDIENT23OV73Q5G99
CALCIUM POLYCARBOPHILINACTIVE INGREDIENT8F049NKY499
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I309
MANNITOLINACTIVE INGREDIENT3OWL53L36A9
POLACRILININACTIVE INGREDIENTRCZ785HI7S9
POTASSIUM BICARBONATEINACTIVE INGREDIENTHM5Z15LEBN9
SODIUM ALGINATEINACTIVE INGREDIENTC269C4G2ZQ9
SODIUM CARBONATEINACTIVE INGREDIENT45P3261C7T9
XANTHAN GUMINACTIVE INGREDIENTTTV12P4NEE9

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0135-05080135-0508-02, 0135-0508-03, 0135-0508-04
0135-05090135-0509-02, 0135-0509-03, 0135-0509-04

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 20 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 44 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / ORAL420 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
CALCIUM POLYCARBOPHILCALCIUM POLYCARBOPHIL8F049NKY49LOZENGE / ORAL480 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
SODIUM CARBONATESODIUM CARBONATE45P3261C7TLOZENGE / ORAL500 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9LOZENGE / ORAL120 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
SODIUM CARBONATESODIUM CARBONATE45P3261C7TLOZENGE / ORAL500 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
CALCIUM POLYCARBOPHILCALCIUM POLYCARBOPHIL8F049NKY49LOZENGE / ORAL480 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
CALCIUM POLYCARBOPHILCALCIUM POLYCARBOPHIL8F049NKY49LOZENGE / ORAL480 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
XANTHAN GUMXANTHAN GUMTTV12P4NEELOZENGE / ORAL1264 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
SODIUM CARBONATESODIUM CARBONATE45P3261C7TLOZENGE / ORAL500 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ALOZENGE / ORAL20546 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POTASSIUM BICARBONATEPOTASSIUM BICARBONATEHM5Z15LEBNLOZENGE / ORAL80 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET / ORAL3 mgExact identifier — unii+route
12 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET / ORAL3 mgExact identifier — unii+route
12 equally ranked IID candidates
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9LOZENGE / ORAL120 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
SODIUM ALGINATESODIUM ALGINATEC269C4G2ZQLOZENGE / ORAL1274 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET / ORAL3 mgExact identifier — unii+route
12 equally ranked IID candidates
XANTHAN GUMXANTHAN GUMTTV12P4NEELOZENGE / ORAL1264 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / ORAL420 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET, ORALLY DISINTEGRATING / ORAL64 mgExact identifier — unii+route
12 equally ranked IID candidates
SODIUM ALGINATESODIUM ALGINATEC269C4G2ZQLOZENGE / ORAL1274 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
CALCIUM POLYCARBOPHILCALCIUM POLYCARBOPHIL8F049NKY49LOZENGE / ORAL480 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / ORAL420 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ALOZENGE / ORAL20546 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET, ORALLY DISINTEGRATING / ORAL64 mgExact identifier — unii+route
12 equally ranked IID candidates
XANTHAN GUMXANTHAN GUMTTV12P4NEELOZENGE / ORAL1264 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9LOZENGE / ORAL120 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
SODIUM CARBONATESODIUM CARBONATE45P3261C7TLOZENGE / ORAL500 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POTASSIUM BICARBONATEPOTASSIUM BICARBONATEHM5Z15LEBNLOZENGE / ORAL80 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POTASSIUM BICARBONATEPOTASSIUM BICARBONATEHM5Z15LEBNLOZENGE / ORAL80 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ALOZENGE / ORAL20546 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
XANTHAN GUMXANTHAN GUMTTV12P4NEELOZENGE / ORAL1264 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / ORAL420 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET, CHEWABLE / ORAL20 mgExact identifier — unii+route
12 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET, CHEWABLE / ORAL20 mgExact identifier — unii+route
12 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET, CHEWABLE / ORAL20 mgExact identifier — unii+route
12 equally ranked IID candidates
SODIUM ALGINATESODIUM ALGINATEC269C4G2ZQLOZENGE / ORAL1274 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POTASSIUM BICARBONATEPOTASSIUM BICARBONATEHM5Z15LEBNLOZENGE / ORAL80 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET, ORALLY DISINTEGRATING / ORAL64 mgExact identifier — unii+route
12 equally ranked IID candidates
SODIUM ALGINATESODIUM ALGINATEC269C4G2ZQLOZENGE / ORAL1274 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9LOZENGE / ORAL120 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET / ORAL3 mgExact identifier — unii+route
12 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET, ORALLY DISINTEGRATING / ORAL64 mgExact identifier — unii+route
12 equally ranked IID candidates
POLACRILINPOLACRILINRCZ785HI7STABLET, CHEWABLE / ORAL20 mgExact identifier — unii+route
12 equally ranked IID candidates
MANNITOLMANNITOL3OWL53L36ALOZENGE / ORAL20546 mgExact identifier — unii+route+dosage form
4 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N022360-001NICORETTENICOTINE POLACRILEXEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18
N022360-002NICORETTENICOTINE POLACRILEXEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18

Orange Book patents#

Current patent rows page 1 of 1 · 4 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N022360-00189407722029-04-30Drug product2015-02-25
N022360-00185011642029-06-14Drug product2013-09-05
N022360-00289407722029-04-30Drug product2015-02-25
N022360-00285011642029-06-14Drug product2013-09-05

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 90 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18d4dbc9d85df4…
2026-11-14 07:37:172026-10N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18d4dbc9d85df4…
2026-10-15 13:18:302026-09N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18c2088c7a36db…
2026-10-15 13:18:302026-09N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18c2088c7a36db…
2026-09-14 22:38:342026-08N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-1884e616aacf4f…
2026-09-14 22:38:342026-08N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-1884e616aacf4f…
2026-08-18 06:07:402026-07N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18caaa826d4ba7…
2026-08-18 06:07:402026-07N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18011fe1cb6892…
2026-02-19 14:30 UTC2026-02N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-1831067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-186a471c1ec25d…
2025-08-23 18:47 UTC2025-08N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-1803ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-182680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-185bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18d06236e962d9…
2024-10-29 15:01 UTC2024-10N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-1879d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-18301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-181e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-188072bd15b7f6…
2024-05-31 18:47 UTC2024-05N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-185c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N022360-001NICORETTEEQ 2MG BASETROCHE/LOZENGE / ORALRLD2009-05-185d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N022360-002NICORETTEEQ 4MG BASETROCHE/LOZENGE / ORALRLD, RS2009-05-185d02ea3f76ae…

Observed Orange Book patent history#

Patent history page 1 of 5 · 180 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-11-14 07:37:172026-10N022360-00189407722029-04-30Drug product2015-02-25d4dbc9d85df4…
2026-11-14 07:37:172026-10N022360-00185011642029-06-14Drug product2013-09-05d4dbc9d85df4…
2026-11-14 07:37:172026-10N022360-00289407722029-04-30Drug product2015-02-25d4dbc9d85df4…
2026-11-14 07:37:172026-10N022360-00285011642029-06-14Drug product2013-09-05d4dbc9d85df4…
2026-10-15 13:18:302026-09N022360-00189407722029-04-30Drug product2015-02-25c2088c7a36db…
2026-10-15 13:18:302026-09N022360-00185011642029-06-14Drug product2013-09-05c2088c7a36db…
2026-10-15 13:18:302026-09N022360-00289407722029-04-30Drug product2015-02-25c2088c7a36db…
2026-10-15 13:18:302026-09N022360-00285011642029-06-14Drug product2013-09-05c2088c7a36db…
2026-09-14 22:38:342026-08N022360-00189407722029-04-30Drug product2015-02-2584e616aacf4f…
2026-09-14 22:38:342026-08N022360-00185011642029-06-14Drug product2013-09-0584e616aacf4f…
2026-09-14 22:38:342026-08N022360-00289407722029-04-30Drug product2015-02-2584e616aacf4f…
2026-09-14 22:38:342026-08N022360-00285011642029-06-14Drug product2013-09-0584e616aacf4f…
2026-08-18 06:07:402026-07N022360-00189407722029-04-30Drug product2015-02-25caaa826d4ba7…
2026-08-18 06:07:402026-07N022360-00185011642029-06-14Drug product2013-09-05caaa826d4ba7…
2026-08-18 06:07:402026-07N022360-00289407722029-04-30Drug product2015-02-25caaa826d4ba7…
2026-08-18 06:07:402026-07N022360-00285011642029-06-14Drug product2013-09-05caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N022360-00189407722029-04-30Drug product2015-02-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02N022360-00185011642029-06-14Drug product2013-09-05011fe1cb6892…
2026-02-19 14:30 UTC2026-02N022360-00289407722029-04-30Drug product2015-02-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02N022360-00285011642029-06-14Drug product2013-09-05011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N022360-00189407722029-04-30Drug product2015-02-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N022360-00185011642029-06-14Drug product2013-09-0531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N022360-00289407722029-04-30Drug product2015-02-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N022360-00285011642029-06-14Drug product2013-09-0531067a03dcf5…
2025-08-23 18:47 UTC2025-08N022360-00189407722029-04-30Drug product2015-02-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08N022360-00185011642029-06-14Drug product2013-09-056a471c1ec25d…
2025-08-23 18:47 UTC2025-08N022360-00289407722029-04-30Drug product2015-02-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08N022360-00285011642029-06-14Drug product2013-09-056a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N022360-00189407722029-04-30Drug product2015-02-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N022360-00185011642029-06-14Drug product2013-09-05fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N022360-00289407722029-04-30Drug product2015-02-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N022360-00285011642029-06-14Drug product2013-09-05fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N022360-00189407722029-04-30Drug product2015-02-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N022360-00185011642029-06-14Drug product2013-09-05b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N022360-00289407722029-04-30Drug product2015-02-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N022360-00285011642029-06-14Drug product2013-09-05b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N022360-00189407722029-04-30Drug product2015-02-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N022360-00185011642029-06-14Drug product2013-09-0503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N022360-00289407722029-04-30Drug product2015-02-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N022360-00285011642029-06-14Drug product2013-09-0503ed91905a0d…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NICORETTENICOTINE POLACRILEXHaleon US Holdings LLCfdee1637-8049-4bc5-b196-b6d854c9f9f32024-03-05WarningsExact identifier
ndc (package): 0135-0508-03
ndc (package): 0135-0508-02
ndc (package): 0135-0509-02
ndc (package): 0135-0509-03
ndc (package): 0135-0509-04
ndc (package): 0135-0508-04
ndc (product): 0135-0508
ndc (product): 0135-0509
ndc11 (package): 00135050803
ndc11 (package): 00135050902
ndc11 (package): 00135050804
ndc11 (package): 00135050904
ndc11 (package): 00135050802
ndc11 (package): 00135050903
spl id: 12f1fec8-003a-8788-e063-6394a90a298a
spl set id: fdee1637-8049-4bc5-b196-b6d854c9f9f3

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.